French pharmaceutical group Servier has quietly become one of the most methodical players in oncology—and its latest move underscores that reputation. The company announced a definitive agreement to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing the…